Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

References

• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014; 14(8):a015354–a015354.
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Lima XT, Minnillo R, Spencer JM, et al. Psoriasis prevalence among the 2009 AAD national melanoma/skin cancer screening program participants. J Eur Acad Dermatol Venereol. 2013;27(6):680–685.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the Population-Based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97.
   PubMed Web of Science ®Google Scholar
• Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.
   Google Scholar
• Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):S216–S24.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265 e19.
   PubMed Web of Science ®Google Scholar
• Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–451.
   PubMed Web of Science ®Google Scholar
• Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220.
   PubMed Web of Science ®Google Scholar
• Bulat V, Situm M, Delas Azdajic M, et al. Study on the impact of psoriasis on quality of life: psychological, social and financial implications. Psychiatr Danub. 2020;32(Suppl 4):553–561.
   PubMedGoogle Scholar
• Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):677–698.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, UNCOVER-3 Study Group, et al. Phase 3 trials of ixekizumab in moderate-to-Severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058.
   PubMed Web of Science ®Google Scholar
• Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70–79 e3.
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, IXORA-S investigators, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, SPIRIT-P1 Study Group, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, SPIRIT H2H study group, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131.
   PubMed Web of Science ®Google Scholar
• Reich K, Kristensen LE, Smith SD, et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-naive patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial. Dermatol Pract Concept. 2022;12(2):e2022104.
   PubMedGoogle Scholar
• US FDA. Real-world evidence 2022. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
   Google Scholar
• European Medicines Agency. Data Analysis and Real World Interrogation Network (DARWIN EU) 2022. 2022. https://www.ema.europa.eu/en/about-us/how-we-work/big-data/data-analysis-real-world-interrogation-network-darwin-eu
   Google Scholar
• National Insitute for Health and Care Excellence. Real-world evidence framework feedback 2022. 2022. https://www.nice.org.uk/about/what-we-do/real-world-evidence-framework-feedback
   Google Scholar
• European Commission. European Health Data Space 2022. 2022. https://ec.europa.eu/health/ehealth-digital-health-and-care/european-health-data-space_en
   Google Scholar
• Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol. 2022;61(3):e107–e108.
   PubMed Web of Science ®Google Scholar
• US FDA. TALTZ (ixekizumab) injection, for subcutaneous use. Prescribing information 2017. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf.
   Google Scholar
• European Medicines Association. Taltz (ixekizumab) 80 mg solution for injection in pre-filled syringe. Summary of product characteristics 2020. 2022. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
   Google Scholar
• Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in Real-World studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1-2):1–12.
   PubMed Web of Science ®Google Scholar
• de la Cueva Dobao P, Notario J, Ferrandiz C, et al. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2019;33(7):1214–1223.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Higgins JPT TJ ,Chandler J ,Cumpston M, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane; 2021. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Shahriari M, Crabtree M, Burge R, et al. Patient-reported outcomes and response to treatment for patients initiating ixekizumab: findings from the corrona registry. J Am Acad Dermatol. 2019;81(4):AB252.
   Web of Science ®Google Scholar
• Shahriari M, Harrison RW, Burge R, et al. Disease response and patient-reported outcomes among initiators of ixekizumab. J Dermatolog Treat. 2020; 2:1–9.
   Google Scholar
• Shahriari M, Harrison RW, Burge R, et al. Disease response outcomes among ixekizumab patients: findings from the corrona registry. J Am Acad Dermatol. 2019;81(4, Supplement 1):AB194.
   Web of Science ®Google Scholar
• Blauvelt A, Burge R, Charbonneau B, et al. 26648 Real-World comparison of monotherapy and concomitant medication use with biologic therapies for psoriasis: ixekizumab vs. Guselkumab. Am Acad Dermatol. 2021;85:19–23.
   Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Lebwohl MG, et al. 16007 ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: results from IBM MarketScan® databases. Am Acad Dermatol. 2020;83:20–24
   Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927–935.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of Real-World treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. Patient Prefer Adherence. 2020;14:517–527.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. 26718 Comparison of Long-Term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients. Am Acad Dermatol. 2021;85:19–23.
   Web of Science ®Google Scholar
• Blauvelt A, Zhu B, Murage M, et al. 26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: real-world results. J Am Acad Dermatol. 2021;85(3):AB111.
   Web of Science ®Google Scholar
• Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(1):173–178.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhang J, Martinez DJ, et al. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis. Dermatol Online J. 2021;27(1):13030.
   Google Scholar
• Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis*. Br J Dermatol. 2021;184(6):1094–1105.
   PubMed Web of Science ®Google Scholar
• Hendrix N, Marcum ZA, Veenstra DL. Medication persistence of targeted immunomodulators for plaque psoriasis: a retrospective analysis using a U.S. claims database. Pharmacoepidemiol Drug Saf. 2020;29(6):675–683.
   PubMed Web of Science ®Google Scholar
• Kemula M, Morand F, De Nascimento J, et al. PBI58 persistence of treatment with biologics for patients with psoriasis: an analysis of a french prescription database. Value Health. 2020;23: s420.
   Web of Science ®Google Scholar
• Leonardi CL, Blauvelt A, Zhu B, et al. 15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: results from IBM MarketScan databases. J Am Acad Dermatol. 2020;83(6):AB52.
   Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corrona psoriasis registry. Dermatol Ther. 2021;34(2):e14808.
   PubMed Web of Science ®Google Scholar
• Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from slovenian national registry of psoriasis. Int J Dermatol. 2019;58(6):631–641.
   PubMed Web of Science ®Google Scholar
• Sherman S, Zloczower O, Noyman Y, et al. Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-Centre retrospective study. Acta Derm Venereol. 2020;100(19):adv00349.
   PubMedGoogle Scholar
• Stelmaszuk-Zadykowicz NM, Apol E, Hansen JB, et al. AD1 persistence of biologic therapies for the treatment of plaque psoriasis - A national longitudinal observational population study in Sweden. Value Health. 2019;22:s403.
   Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective Multi-Country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021;21(2):279–286.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Lam K, Sandhu VK, et al. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. J Eur Acad Dermatol Venereol. 2020;34(8):e416–e418.
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2020b;33(6):e14202.
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther. 2020a;33(3):e13313.
   PubMed Web of Science ®Google Scholar
• Pinter A, Constanzo A, Gooderham M, et al. Initial Report from the Psoriasis Study of Health Outcomes (PSoHO) on baseline characteristics and week 12 results in psoriasis patients treated with biologics in a real world setting. EADV Virtual. 2020.
   Google Scholar
• Georgakopoulos JR, Phung M, Ighani A, et al. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol. 2019;33(1):e7–e8.
   PubMed Web of Science ®Google Scholar
• Apol E, Delgado Perala M. 6ER-011 modelling the impact of discounts on the real-life cost-effectiveness of biologic therapies in the treatment of moderate-to-severe plaque psoriasis in Spain. Eur J Hosp Pharm. 2019;26(Suppl 1):A282–A283.
   Google Scholar
• Blauvelt A, Shi N, Zhu B, et al. Comparison of health care costs among patients with psoriasis initiating ixekizumab, secukinumab, or adalimumab. J Manag Care Spec Pharm. 2019;25(12):1366–1376.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Gara A, Amato D, et al. Disease severity and quality of life among ixekizumab-treated psoriasis patients in the real-world setting: results from a single US dermatology referral practice. J Am Acad Dermatol. 2019;81(4):AB47.
   Web of Science ®Google Scholar
• Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-Severe psoriasis: long-Term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431–447.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Tao R, Setayeshgar S, et al. 14216 Long-term treatment effects of ixekizumab among psoriasis patients who achieved early high-level treatment outcomes in a real-world setting: results from a single US dermatology referral practice. J Am Acad Dermatol. 2020;83(6):AB133.
   Google Scholar
• Sherman S, Solomon Cohen E, Amitay-Laish I, et al. IL-17A inhibitor Switching - Efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol. 2019; 199(9):769–773.
   PubMed Web of Science ®Google Scholar
• Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547–1548.
   PubMed Web of Science ®Google Scholar
• Damiani G, Conic RRZ, Pigatto PDM, Young Dermatologists Italian Network, et al. From randomized clinical trials to real life data. An italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019;32(3):e12886.
   PubMed Web of Science ®Google Scholar
• Briceño Casado M, Gil-Sierra M, De La Calle Riaguas B, et al. 4CPS-324 effectiveness and safety of ixekizumab in moderate-to-severe plaque psoriasis. Eur J Hosp Pharm. 2021;28(Suppl 1):A76.3–A77.
   Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-Severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Phung M, Ighani A, et al. Ixekizumab (interleukin 17A antagonist): 12-week efficacy and safety outcomes in real-world clinical practice. J Cutan Med Surg. 2019;23(2):174–177.
   PubMed Web of Science ®Google Scholar
• Goon PKC, Lim H-Y, Summerfield L, et al. Real-world experience and analyses of the performance of ixekizumab as first-line biologic agent versus second-line (or higher) biologic agent in the treatment of chronic plaque psoriasis. Int J Dermatol. 2021;60(8):e319–e320.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatol Treat. 2020;33(1):354–360.
   PubMed Web of Science ®Google Scholar
• Hampton PS, Meeks AC, Arx LB, et al. PBI53 initiation of ixekizumab in patients with psoriasis and follow-up assessment in the badbir registry. Value Health. 2020;23: s419. 12/01
   Web of Science ®Google Scholar
• Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, et al. Efficacy and safety of ixekizumab in a Real-Life practice: a retrospective bicentric study. Actas Dermo-Sifiliográficas (English Edition). 2019;110(7):585–589. 2019/09/01/
   Google Scholar
• Rivera R, Velasco M, Vidal D, et al. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a spanish multicentre retrospective study. Dermatol Ther. 2020;33(6):e14066.
   PubMed Web of Science ®Google Scholar
• Sendín-Martín M, Barabash-Neila R, Durán-Romero A, et al. 15906 Efficacy and safety of ixekizumab in real-world psoriasis patients: a retrospective unicentre study. J Am Acad Dermatol. 2020;83(6):AB163. 12/01
   Web of Science ®Google Scholar
• Grace E, Zhu B, Malley W, et al. P001 safety events occurring among patients exposed to ixekizumab in the corrona psoriasis registry. J Eur Acad Dermatol Venereol. 2019;33(S3):3–19.
   Google Scholar
• Perrone V. Losi S, Maiorino A, et al. Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian real-world setting. Drugs Real World Outcomes. 2022;9(2):243–251.
   Google Scholar
• Wu JJ, Zhu B, Burge R, et al. Real world use of ixekizumab is associated with reductions in concomitant medications among biologic-experienced or biologic-naive patients with psoriasis. J Am Acad Dermatol. 2019;81(4):AB114.
   Web of Science ®Google Scholar
• Murage MJ, Gilligan AM, Tran O, et al. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. J Dermatolog Treat. 2021;32(1):56–63.
   PubMed Web of Science ®Google Scholar
• Manfreda V, Chimenti MS, Canofari C, et al. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-Centre, observational study in a real-life clinical setting. Clin Exp Rheumatol. 2020;38(3):581–582.
   PubMed Web of Science ®Google Scholar
• Murage M, Princic N, Park J, et al. Real world treatment patterns among patients with psoriatic arthritis treated with ixekizumab. Arthritis Rheumatol. 2020;72(suppl 10). [Accessed 22 December 2022]. https://acrabstracts.org/abstract/real-world-treatment-patterns-among-patients-with-psoriatic-arthritis-treated-with-ixekizumab/
   Google Scholar
• Murage MJ, Princic N, Park J, et al. Real-World healthcare resource utilization and costs of patients with psoriatic arthritis treated with ixekizumab. J Manag Care Spec Pharm. 2020;26(10a):S1–S101.
   Google Scholar
• Pinter A, Puig L, Schakel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Acad Dermatol Venereol. 2022;36(11):2087–2100. Jun 29.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064–1071.
   PubMed Web of Science ®Google Scholar
• Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73–86.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Torisu-Itakura H, Nishikawa A, Japanese UNCOVER-1 Study Group, et al. Efficacy and safety of ixekizumab treatment in japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1). J Dermatol. 2017;44(11):1285–1290.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017;20(12):1224–1230.
   PubMed Web of Science ®Google Scholar